Chemistry:Lotiglipron
From HandWiki
Short description: Chemical compound
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C31H31ClN4O5 |
| Molar mass | 575.06 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Pfizer.[1] It was withdrawn from development after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.[2]
See also
- Danuglipron
- Orforglipron
References
- ↑ Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", US patent 10676465, issued 9 June 2020, assigned to Pfizer Inc
- ↑ "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns.". Time. 26 June 2023. https://time.com/6290227/pfizer-shares-drop-after-lotiglipron-pause/.
